Site icon pharmaceutical daily

Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape” report has been added to ResearchAndMarkets.com’s offering.

This reports provides a data-driven overview of the current and future competitive landscape in AC therapeutics.

There will be more than 1 billion prevalent cases of AC in 2023 in the 16 countries covered in the publisher’s epidemiology forecast for AC. The innovator marketed drugs space for AC mainly consists of dual-acting antihistamines and mast cell inhibitors. R&D activity in AC is promising with four drugs in Phase III and 10 drugs in Phase II of development.

Clinical trial space in AC mainly includes commercial sponsors, with the US emerging as the key country for conducting Phase III trials. Two strategic alliances and one merger & acquisition involving companies developing AC assets were successfully completed in the past two years.

Components of the report include:

Key Topics Covered:

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Route of Administration

4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

5.1 Annual Therapy Cost

5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

6.1 Phase III Pipeline Drugs

6.2 Overview by Development Stage

6.3 Overview by Molecule Type

6.4 Overview by Mechanism of Action

6.5 Overview by Route of Administration

6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

7.1 Historical Overview

7.2 Overview by Phase

7.3 Overview by Status

7.4 Overview by Phase for Ongoing and Planned Trials

7.5 Trials with Virtual Components

7.6 Geographic Overview

7.7 Single-Country and Multinational Trials by Region

7.8 Top 20 Sponsors with Breakdown by Phase

7.9 Top 20 Sponsors with Breakdown by Status

7.10 Overview by Endpoint Status

7.11 Overview by Race and Ethnicity

7.12 Enrollment Data

7.13 Top 20 countries for Trial Sites

7.14 Top 20 Sites Globally

7.15 Feasibility Analysis – Geographic Overview

7.16 Feasibility Analysis – Benchmark Models

8 Deals Landscape

8.1 Mergers, Acquisitions, and Strategic Alliances by Region

8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

9.1 Key Market Players

10 Future Market Catalysts

For more information about this report visit https://www.researchandmarkets.com/r/v7379d

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version